Quality of Life in Epilepsy-89 (QOLIE-89)
Also known as: QoLIE-89
The QOLIE-89 is a comprehensive disease-specific quality-of-life instrument developed specifically for people with epilepsy. Introduced by Devinsky and colleagues in 1995, it captures the broad impact of epilepsy on physical, emotional, social, and cognitive functioning. With 89 items organized into 17 distinct domains, it remains one of the most detailed QoL assessments for epilepsy and is widely used in clinical trials, health services research, and outcome monitoring.
Key highlights
- 17 domains provide granular understanding of which aspects of life are most affected by epilepsy, enabling targeted intervention
- Comprehensive coverage of epilepsy-specific concerns (seizure worry, driving, medication side effects, stigma) often missed by generic QoL instruments
- Well-validated across diverse epilepsy populations (focal and generalized, controlled and uncontrolled seizures, various ages)
- Strong psychometric properties with documented internal consistency, test-retest reliability, and sensitivity to clinical change
- Widely translated and used internationally, facilitating multi-center trials and cross-cultural research
Intuition
This section is available to Pro members. Upgrade to Pro
How it works
This section is available to Pro members. Upgrade to Pro
When to use it
QOLIE-89 is the preferred instrument for comprehensive QoL assessment in epilepsy clinical trials, particularly when evaluating new antiepileptic drugs or surgical interventions where side effects and patient perception matter. It is valuable in longitudinal cohort studies tracking QoL trajectories across years, routine clinical practice for detailed patient-reported outcomes monitoring, health services research evaluating rehabilitation, employment support, or psychosocial interventions, and comparative effectiveness studies. Less suitable when only brief screening is needed (shorter QOLIE-31 may be preferable) or when rapid serial assessments are required (burden of 89 items may be prohibitive).
Strengths & limitations
- 17 domains provide granular understanding of which aspects of life are most affected by epilepsy, enabling targeted intervention
- Comprehensive coverage of epilepsy-specific concerns (seizure worry, driving, medication side effects, stigma) often missed by generic QoL instruments
- Well-validated across diverse epilepsy populations (focal and generalized, controlled and uncontrolled seizures, various ages)
- Strong psychometric properties with documented internal consistency, test-retest reliability, and sensitivity to clinical change
- Widely translated and used internationally, facilitating multi-center trials and cross-cultural research
- 89 items require substantial completion time (20-25 minutes), leading to potential respondent fatigue in some settings
- Requires interpretation of 17 separate domain scores rather than a single summary metric, which may be less convenient in routine clinic
- Some domains (e.g., Driving Concern) may be less relevant to patients unable to drive at baseline
- Minimal Clinically Important Difference (MCID) varies by domain and population; not all have well-established thresholds
Common pitfalls
This section is available to Pro members. Upgrade to Pro
Applications
This section is available to Pro members. Upgrade to Pro
Frequently asked
Should I use QOLIE-89 or the shorter QOLIE-31?
QOLIE-89 provides 17 domain scores and detailed assessment; QOLIE-31 (derived subset) is briefer (about 10 minutes) and suitable for routine clinic. Use QOLIE-89 in research trials or when comprehensive QoL profiling is needed. Use QOLIE-31 for rapid screening or when respondent burden must be minimized. Both correlate well with each other; the choice depends on context and available time.
Is a score of 50 on the Seizure Worry domain considered good or concerning?
A score of 50 (on a 0-100 scale) indicates moderate worry about seizures. Higher scores (70+) suggest well-managed worry despite living with epilepsy; lower scores (0-30) suggest substantial worry that may warrant cognitive-behavioral intervention or reassurance. Context matters—a patient with daily uncontrolled seizures at 50 on Worry may need seizure treatment optimization, whereas a seizure-free patient at 40 suggests ongoing anxiety despite control that could benefit from psychological support.
Can QOLIE-89 be used in pediatric epilepsy?
The standard QOLIE-89 is validated for ages 18+. For children and adolescents, the QOLIE-AD (adolescent) version exists and is recommended. Some adult centers have used adapted QOLIE-89 in older teens (16+) with careful attention to item comprehension, but the pediatric-specific version is preferable for developmental appropriateness and validated psychometrics.
How do I interpret a large drop in Medication Effects score between two administrations?
A significant decline in Medication Effects domain (e.g., from 60 to 35) may indicate emergence of intolerable side effects, dose escalation, or addition of medications with greater side burden. This is a signal to review medication regimen with the patient and discuss tolerability. Combined with stable seizure control, it may warrant medication adjustment. Conversely, improvement in this domain after medication change suggests the switch was tolerated well from a QoL perspective.
Sources
- 1.Devinsky, O., Vickrey, B. G., Cramer, J., Edwards, B., Perrine, K., Hamberger, M. J., & Towle, V. L. (1995). Development of the Quality of Life in Epilepsy Inventory. Epilepsia, 36(11), 1089-1104.
You have read it. What now?
Cite this page
ScholarGate. (2026, June 3). QOLIE-89. ScholarGate. https://scholargate.app/neurology/qolie-89